Regeneus Ltd
Get $10 bonus on your first $100 deposit for RGS.AX
Get $10 bonus on your first $100 deposit for RGS.AX
Regeneus Ltd (RGS.AX) Stock Competitors & Peer Comparison
See (RGS.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGS.AX | A$0.01 | +33.33% | 3.7M | -1.20 | -A$0.01 | N/A |
| CSL.AX | A$138.93 | -2.28% | 67.4B | 15.42 | A$9.01 | +3.08% |
| TLX.AX | A$12.95 | -1.89% | 4.4B | -431.67 | -A$0.03 | N/A |
| MSB.AX | A$2.13 | -6.17% | 2.7B | -19.36 | -A$0.11 | N/A |
| NEU.AX | A$12.03 | -2.51% | 1.5B | 52.30 | A$0.23 | N/A |
| CU6.AX | A$3.15 | -5.12% | 1.2B | -11.25 | -A$0.28 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | -1.40 | -A$0.43 | N/A |
| PYC.AX | A$1.12 | -4.29% | 650.1M | -13.94 | -A$0.08 | N/A |
| RAC.AX | A$2.63 | +0.00% | 478.6M | -52.60 | -A$0.05 | N/A |
| CUV.AX | A$9.02 | -7.39% | 452.7M | 14.09 | A$0.64 | +0.55% |
Stock Comparison
RGS.AX vs CSL.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CSL.AX has a market cap of 67.4B. Regarding current trading prices, RGS.AX is priced at A$0.01, while CSL.AX trades at A$138.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CSL.AX's P/E ratio is 15.42. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, RGS.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check CSL.AX's competition here
RGS.AX vs TLX.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, TLX.AX has a market cap of 4.4B. Regarding current trading prices, RGS.AX is priced at A$0.01, while TLX.AX trades at A$12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas TLX.AX's P/E ratio is -431.67. In terms of profitability, RGS.AX's ROE is +4.56%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, RGS.AX is more volatile compared to TLX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check TLX.AX's competition here
RGS.AX vs MSB.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, MSB.AX has a market cap of 2.7B. Regarding current trading prices, RGS.AX is priced at A$0.01, while MSB.AX trades at A$2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas MSB.AX's P/E ratio is -19.36. In terms of profitability, RGS.AX's ROE is +4.56%, compared to MSB.AX's ROE of -0.14%. Regarding short-term risk, RGS.AX is more volatile compared to MSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check MSB.AX's competition here
RGS.AX vs NEU.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NEU.AX has a market cap of 1.5B. Regarding current trading prices, RGS.AX is priced at A$0.01, while NEU.AX trades at A$12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NEU.AX's P/E ratio is 52.30. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, RGS.AX is more volatile compared to NEU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NEU.AX's competition here
RGS.AX vs CU6.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CU6.AX has a market cap of 1.2B. Regarding current trading prices, RGS.AX is priced at A$0.01, while CU6.AX trades at A$3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CU6.AX's P/E ratio is -11.25. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CU6.AX's ROE of -0.60%. Regarding short-term risk, RGS.AX is more volatile compared to CU6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check CU6.AX's competition here
RGS.AX vs OPT.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, RGS.AX's ROE is +4.56%, compared to OPT.AX's ROE of +1.32%. Regarding short-term risk, RGS.AX is more volatile compared to OPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check OPT.AX's competition here
RGS.AX vs PYC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PYC.AX has a market cap of 650.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PYC.AX trades at A$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PYC.AX's P/E ratio is -13.94. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, RGS.AX is more volatile compared to PYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PYC.AX's competition here
RGS.AX vs RAC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, RAC.AX has a market cap of 478.6M. Regarding current trading prices, RGS.AX is priced at A$0.01, while RAC.AX trades at A$2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas RAC.AX's P/E ratio is -52.60. In terms of profitability, RGS.AX's ROE is +4.56%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, RGS.AX is more volatile compared to RAC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check RAC.AX's competition here
RGS.AX vs CUV.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CUV.AX has a market cap of 452.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while CUV.AX trades at A$9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CUV.AX's P/E ratio is 14.09. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, RGS.AX is more volatile compared to CUV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check CUV.AX's competition here
RGS.AX vs SPL.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, SPL.AX has a market cap of 210M. Regarding current trading prices, RGS.AX is priced at A$0.01, while SPL.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas SPL.AX's P/E ratio is -50.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, RGS.AX is more volatile compared to SPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check SPL.AX's competition here
RGS.AX vs DXB.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, DXB.AX has a market cap of 192.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while DXB.AX trades at A$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas DXB.AX's P/E ratio is -10.67. In terms of profitability, RGS.AX's ROE is +4.56%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, RGS.AX is more volatile compared to DXB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check DXB.AX's competition here
RGS.AX vs OCC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, OCC.AX has a market cap of 178.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while OCC.AX trades at A$0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas OCC.AX's P/E ratio is -16.10. In terms of profitability, RGS.AX's ROE is +4.56%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, RGS.AX is more volatile compared to OCC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check OCC.AX's competition here
RGS.AX vs RCE.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, RCE.AX has a market cap of 134.5M. Regarding current trading prices, RGS.AX is priced at A$0.01, while RCE.AX trades at A$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas RCE.AX's P/E ratio is -4.23. In terms of profitability, RGS.AX's ROE is +4.56%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, RGS.AX is more volatile compared to RCE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check RCE.AX's competition here
RGS.AX vs ACW.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ACW.AX has a market cap of 132.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ACW.AX's P/E ratio is -3.70. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, RGS.AX is more volatile compared to ACW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ACW.AX's competition here
RGS.AX vs NYR.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NYR.AX has a market cap of 124.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while NYR.AX trades at A$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NYR.AX's P/E ratio is -31.25. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NYR.AX's ROE of -0.83%. Regarding short-term risk, RGS.AX is more volatile compared to NYR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NYR.AX's competition here
RGS.AX vs ATX.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ATX.AX has a market cap of 123.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ATX.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ATX.AX's P/E ratio is -12.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ATX.AX's ROE of -0.25%. Regarding short-term risk, RGS.AX is more volatile compared to ATX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ATX.AX's competition here
RGS.AX vs PAR.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PAR.AX has a market cap of 115.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PAR.AX trades at A$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PAR.AX's P/E ratio is -2.60. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, RGS.AX is more volatile compared to PAR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PAR.AX's competition here
RGS.AX vs PAA.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, RGS.AX is more volatile compared to PAA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PAA.AX's competition here
RGS.AX vs ATH.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ATH.AX has a market cap of 97.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ATH.AX's P/E ratio is -0.90. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, RGS.AX is more volatile compared to ATH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ATH.AX's competition here
RGS.AX vs ILA.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ILA.AX has a market cap of 93.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ILA.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ILA.AX's P/E ratio is -12.50. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, RGS.AX is more volatile compared to ILA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ILA.AX's competition here
RGS.AX vs BOT.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BOT.AX has a market cap of 88.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BOT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BOT.AX's P/E ratio is -0.80. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, RGS.AX is more volatile compared to BOT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BOT.AX's competition here
RGS.AX vs ALA.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ALA.AX has a market cap of 83.3M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ALA.AX's P/E ratio is -6.90. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, RGS.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ALA.AX's competition here
RGS.AX vs BIO.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BIO.AX has a market cap of 77.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BIO.AX trades at A$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BIO.AX's P/E ratio is -34.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, RGS.AX is more volatile compared to BIO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BIO.AX's competition here
RGS.AX vs CYP.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CYP.AX has a market cap of 70M. Regarding current trading prices, RGS.AX is priced at A$0.01, while CYP.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CYP.AX's P/E ratio is -7.37. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, RGS.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check CYP.AX's competition here
RGS.AX vs IMM.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, IMM.AX has a market cap of 64.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while IMM.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas IMM.AX's P/E ratio is -0.73. In terms of profitability, RGS.AX's ROE is +4.56%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, RGS.AX is more volatile compared to IMM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check IMM.AX's competition here
RGS.AX vs NUZ.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NUZ.AX has a market cap of 57.4M. Regarding current trading prices, RGS.AX is priced at A$0.01, while NUZ.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NUZ.AX's P/E ratio is -2.70. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NUZ.AX's ROE of -2.54%. Regarding short-term risk, RGS.AX is more volatile compared to NUZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NUZ.AX's competition here
RGS.AX vs PTX.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PTX.AX has a market cap of 54.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PTX.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PTX.AX's P/E ratio is -5.20. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, RGS.AX is more volatile compared to PTX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PTX.AX's competition here
RGS.AX vs IMU.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, IMU.AX has a market cap of 51.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while IMU.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas IMU.AX's P/E ratio is -0.63. In terms of profitability, RGS.AX's ROE is +4.56%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, RGS.AX is more volatile compared to IMU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check IMU.AX's competition here
RGS.AX vs RAD.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, RAD.AX has a market cap of 49.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas RAD.AX's P/E ratio is -1.05. In terms of profitability, RGS.AX's ROE is +4.56%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, RGS.AX is more volatile compared to RAD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check RAD.AX's competition here
RGS.AX vs ENP.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ENP.AX has a market cap of 48.5M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, RGS.AX is more volatile compared to ENP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ENP.AX's competition here
RGS.AX vs EZZ.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, EZZ.AX has a market cap of 38.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while EZZ.AX trades at A$0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas EZZ.AX's P/E ratio is 13.50. In terms of profitability, RGS.AX's ROE is +4.56%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, RGS.AX is more volatile compared to EZZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check EZZ.AX's competition here
RGS.AX vs PIQ.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PIQ.AX has a market cap of 38M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PIQ.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PIQ.AX's P/E ratio is -3.29. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PIQ.AX's ROE of -0.94%. Regarding short-term risk, RGS.AX is more volatile compared to PIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PIQ.AX's competition here
RGS.AX vs ADO.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ADO.AX has a market cap of 35.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ADO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ADO.AX's P/E ratio is -1.20. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ADO.AX's ROE of -1.42%. Regarding short-term risk, RGS.AX is more volatile compared to ADO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ADO.AX's competition here
RGS.AX vs NSB.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NSB.AX has a market cap of 33.3M. Regarding current trading prices, RGS.AX is priced at A$0.01, while NSB.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NSB.AX's P/E ratio is -5.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, RGS.AX is more volatile compared to NSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NSB.AX's competition here
RGS.AX vs 1AI.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, 1AI.AX has a market cap of 27.4M. Regarding current trading prices, RGS.AX is priced at A$0.01, while 1AI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, RGS.AX's ROE is +4.56%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, RGS.AX is more volatile compared to 1AI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check 1AI.AX's competition here
RGS.AX vs AVE.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, AVE.AX has a market cap of 26.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, RGS.AX's ROE is +4.56%, compared to AVE.AX's ROE of -3.70%. Regarding short-term risk, RGS.AX is more volatile compared to AVE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check AVE.AX's competition here
RGS.AX vs LCT.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, RGS.AX is priced at A$0.01, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, RGS.AX's ROE is +4.56%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, RGS.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check LCT.AX's competition here
RGS.AX vs NC6.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NC6.AX has a market cap of 24.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while NC6.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NC6.AX's P/E ratio is -7.40. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, RGS.AX is more volatile compared to NC6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NC6.AX's competition here
RGS.AX vs AGN.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, AGN.AX has a market cap of 19.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while AGN.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas AGN.AX's P/E ratio is -1.94. In terms of profitability, RGS.AX's ROE is +4.56%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, RGS.AX is more volatile compared to AGN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check AGN.AX's competition here
RGS.AX vs KZA.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, RGS.AX's ROE is +4.56%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, RGS.AX is more volatile compared to KZA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check KZA.AX's competition here
RGS.AX vs NOX.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, NOX.AX has a market cap of 18.4M. Regarding current trading prices, RGS.AX is priced at A$0.01, while NOX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas NOX.AX's P/E ratio is -3.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, RGS.AX is more volatile compared to NOX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check NOX.AX's competition here
RGS.AX vs BTC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BTC.AX has a market cap of 17.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BTC.AX's P/E ratio is 5.50. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, RGS.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BTC.AX's competition here
RGS.AX vs MDC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, RGS.AX's ROE is +4.56%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, RGS.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check MDC.AX's competition here
RGS.AX vs BNO.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, RGS.AX is more volatile compared to BNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BNO.AX's competition here
RGS.AX vs MEM.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, MEM.AX has a market cap of 12.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while MEM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, RGS.AX's ROE is +4.56%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, RGS.AX is more volatile compared to MEM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check MEM.AX's competition here
RGS.AX vs BGT.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BGT.AX has a market cap of 10.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BGT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BGT.AX's P/E ratio is -3.30. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, RGS.AX is more volatile compared to BGT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BGT.AX's competition here
RGS.AX vs TRP.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, TRP.AX has a market cap of 9.7M. Regarding current trading prices, RGS.AX is priced at A$0.01, while TRP.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas TRP.AX's P/E ratio is -2.67. In terms of profitability, RGS.AX's ROE is +4.56%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, RGS.AX is more volatile compared to TRP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check TRP.AX's competition here
RGS.AX vs CMB.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CMB.AX has a market cap of 9.4M. Regarding current trading prices, RGS.AX is priced at A$0.01, while CMB.AX trades at A$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CMB.AX's P/E ratio is -2.93. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, RGS.AX is more volatile compared to CMB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check CMB.AX's competition here
RGS.AX vs PAB.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, PAB.AX has a market cap of 9.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while PAB.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas PAB.AX's P/E ratio is -1.35. In terms of profitability, RGS.AX's ROE is +4.56%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, RGS.AX is more volatile compared to PAB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check PAB.AX's competition here
RGS.AX vs CHM.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, CHM.AX has a market cap of 8.8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas CHM.AX's P/E ratio is -0.20. In terms of profitability, RGS.AX's ROE is +4.56%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, RGS.AX is less volatile compared to CHM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for RGS.AX.Check CHM.AX's competition here
RGS.AX vs VBS.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, VBS.AX has a market cap of 8M. Regarding current trading prices, RGS.AX is priced at A$0.01, while VBS.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas VBS.AX's P/E ratio is -5.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, RGS.AX is more volatile compared to VBS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check VBS.AX's competition here
RGS.AX vs IXC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, IXC.AX has a market cap of 7.5M. Regarding current trading prices, RGS.AX is priced at A$0.01, while IXC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas IXC.AX's P/E ratio is -10.00. In terms of profitability, RGS.AX's ROE is +4.56%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, RGS.AX is more volatile compared to IXC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check IXC.AX's competition here
RGS.AX vs IMC.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, IMC.AX has a market cap of 7.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while IMC.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas IMC.AX's P/E ratio is -1.40. In terms of profitability, RGS.AX's ROE is +4.56%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, RGS.AX is more volatile compared to IMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check IMC.AX's competition here
RGS.AX vs ZLD.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ZLD.AX's P/E ratio is -1.56. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, RGS.AX is more volatile compared to ZLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ZLD.AX's competition here
RGS.AX vs ACR.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ACR.AX has a market cap of 4.5M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ACR.AX's P/E ratio is -1.10. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, RGS.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ACR.AX's competition here
RGS.AX vs BIT.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, BIT.AX has a market cap of 4.1M. Regarding current trading prices, RGS.AX is priced at A$0.01, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas BIT.AX's P/E ratio is -0.25. In terms of profitability, RGS.AX's ROE is +4.56%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, RGS.AX is more volatile compared to BIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check BIT.AX's competition here
RGS.AX vs HXL.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, RGS.AX is priced at A$0.01, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, RGS.AX's ROE is +4.56%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, RGS.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check HXL.AX's competition here
RGS.AX vs EX1.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, RGS.AX's ROE is +4.56%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, RGS.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check EX1.AX's competition here
RGS.AX vs ANR.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, ANR.AX has a market cap of 1.9M. Regarding current trading prices, RGS.AX is priced at A$0.01, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas ANR.AX's P/E ratio is -0.90. In terms of profitability, RGS.AX's ROE is +4.56%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, RGS.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check ANR.AX's competition here
RGS.AX vs 1AD.AX Comparison April 2026
RGS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGS.AX stands at 3.7M. In comparison, 1AD.AX has a market cap of 522.2K. Regarding current trading prices, RGS.AX is priced at A$0.01, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGS.AX currently has a P/E ratio of -1.20, whereas 1AD.AX's P/E ratio is -0.40. In terms of profitability, RGS.AX's ROE is +4.56%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, RGS.AX is more volatile compared to 1AD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RGS.AX.Check 1AD.AX's competition here